Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Thomas MartinSaad Z UsmaniJesus G BerdejaMounzer AghaAdam David CohenParameswaran N HariDavid AviganAbhinav DeolMyo HtutAlexander LesokhinNikhil C MunshiElizabeth O'DonnellA Keith StewartJordan M SchecterJenna D GoldbergCarolyn C JacksonTzu-Min YehArnob BanerjeeAlicia AllredEnrique ZudaireWilliam DeraedtYunsi OlyslagerChangwei ZhouLida PacaudDeepu MadduriAndrzej J JakubowiakYi LinSundar JagannathPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
At approximately 28 months MFU, patients treated with cilta-cel maintained deep and durable responses, observed in both standard and high-risk subgroups. The risk/benefit profile of cilta-cel remained favorable with longer follow-up.